Literature DB >> 10469435

Intracranial gliomas in neurofibromatosis type 1.

R Listernick1, J Charrow, D H Gutmann.   

Abstract

Optic pathway gliomas and brainstem gliomas are the predominant intracranial neoplasms associated with neurofibromatosis type 1 (NF1). Before the past 15 years, studies of optic pathway gliomas in NF1 were hampered by the inaccurate diagnosis of NF1, the unavailability of noninvasive neuroimaging techniques, and the frequent rendering of what would now be considered unnecessary, overly aggressive therapy. When studied systematically, these tumors behave in a much more benign fashion than their counterparts in children who do not have NF1. While they may cause symptoms in as many of 50% of cases, progression to the point where specific intervention is deemed necessary is unusual. Consequently, screening neuroimaging of asymptomatic patients is unwarranted. Because optic pathway tumors universally arise in children younger than 7 years of age, all such children should undergo yearly ophthalmologic evaluations and annual assessments of growth to monitor for signs of precocious puberty. Am. J. Med. Genet. (Semin. Med. Genet.) 89:38-44, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10469435     DOI: 10.1002/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  42 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  MRI internal segmentation of optic pathway gliomas: clinical implementation of a novel algorithm.

Authors:  Ben Shofty; Lior Weizman; Leo Joskowicz; Shlomi Constantini; Anat Kesler; Dafna Ben-Bashat; Michal Yalon; Rina Dvir; Sigal Freedman; Jonathan Roth; Liat Ben-Sira
Journal:  Childs Nerv Syst       Date:  2011-03-31       Impact factor: 1.475

4.  Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma.

Authors:  Xianzhen Chen; Weidong Zang; Fei Xue; Zhaoli Shen; Quanbin Zhang
Journal:  Neurol Sci       Date:  2012-09-30       Impact factor: 3.307

Review 5.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

6.  Natural history and management of low-grade glioma in NF-1 children.

Authors:  Pablo Hernáiz Driever; Stephan von Hornstein; Torsten Pietsch; Rolf Kortmann; Monika Warmuth-Metz; Angela Emser; Astrid K Gnekow
Journal:  J Neurooncol       Date:  2010-03-30       Impact factor: 4.130

Review 7.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

8.  Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.

Authors:  Mustafa Hepokur; Ahmet Murat Sarici
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-12       Impact factor: 3.117

9.  ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.

Authors:  Yuan Wang; Edward Kim; Xiaojing Wang; Bennett G Novitch; Kazuaki Yoshikawa; Long-Sheng Chang; Yuan Zhu
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

10.  Diencephalic syndrome as sign of tumor progression in a child with neurofibromatosis type 1 and optic pathway glioma: a case report.

Authors:  Maria Elena Cavicchiolo; Enrico Opocher; Marco Daverio; Matteo Bendini; Elisabetta Viscardi; Gianni Bisogno; Giorgio Perilongo; Liviana Da Dalt
Journal:  Childs Nerv Syst       Date:  2013-04-25       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.